SynthesisOncotarget2017
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma.Clinical lung cancer · 2026Observational
- Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation.Cancer biology & therapy · 2025Review
- Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.Molecular biomedicine · 2025Review
- Review
- Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin.Scientific reports · 2025Article
- Targeted Therapy in Mesotheliomas: Uphill All the Way.Cancers · 2024Review
- Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.Thoracic cancer · 2024Article
- Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.Journal of clinical medicine · 2023Review
- High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.Histopathology · 2023Article
- Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.Frontiers in immunology · 2023Article
- Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma.Archives of medical science : AMS · 2023Article
- Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients.Journal of personalized medicine · 2021Article
- Biological basis for novel mesothelioma therapies.British journal of cancer · 2021Review
- Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.Cancers · 2021Review
- Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma.Oncology letters · 2021Article
- Three tumor markers for improved efficacy in the management of patients with malignant pleural mesothelioma.Journal of thoracic disease · 2020Article
- Multiplex Soluble Biomarker Analysis from Pleural Effusion.Biomolecules · 2020Article
- Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.Radiology and oncology · 2020Article
- Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos.Cancer management and research · 2019Review
- Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.Cancers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSoluble mesothelin is beneficial to detect the progression and the treatment response of malignant pleural mesothelioma. However, the prognostic value of soluble mesothelin in malignant pleural mesothelioma remains unclear.
methodsHazard ratio with 95% CI was used to evaluate the prognostic value of soluble mesothelin and the effect of clinicopathological characteristics on the survival of malignant pleural mesothelioma.
resultsEight eligible studies involving 579 patients were selected for this meta-analysis. The results showed that soluble mesothelin level was significantly correlated with the survival of malignant pleural mesothelioma (pooled HR: 1.958, 95%CI: 1.531-2.504, p = 0.000; heterogeneity test: I2 = 1.1%, p = 0.421). In addition, the survival of malignant pleural mesothelioma was significantly correlated with some clinicopathological characteristics such as tumor histology (HR = 3.214, 95% CI = 2.071-4.988, p = 0.000; heterogeneity test: I2 = 0.0%, p = 0.623) and tumor stage (HR = 2.007; 95% CI = 1.477-2.727; p = 0.000; heterogeneity test: I2 = 0.0%, p = 0.966).
conclusionsThe survival of malignant pleural mesothelioma is significantly correlated with tumor histology and tumor stage. Furthermore, high soluble mesothelin level may lead to a poor prognosis for malignant pleural mesothelioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.